EGFR tyrosine kinase inhibitors (TKIs), such as first-generation gefitinib and erlotinib, second-generation afatinib, and third-generation osimertinib, provide significant clinical benefit in patients with EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.